Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 5/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358152 | 1.00 | DRD2 (0.58) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL17411224 | 0.89 | DRD2 (0.51) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL15436281 | 0.85 | DRD2 (0.54) | DRD2SIGMAR1DRD3HTR6DRD1 | |
| SCHEMBL17411321 | 0.85 | DRD2 (0.58) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL17364178 | 0.83 | DRD2 (0.47) | DRD2SIGMAR1DRD3NR1H2NR1H3 | |
| SCHEMBL24489447 | 0.82 | DRD2 (0.56) | DRD2SIGMAR1DRD3HTR6SLC18A3 | |
| SCHEMBL24612002 | 0.79 | DRD2 (0.66) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL17411249 | 0.76 | DRD2 (0.51) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL10181371 | 0.76 | DRD2 (0.62) | DRD2SIGMAR1DRD3HTR6KIF18A | |
| SCHEMBL10180278 | 0.74 | DRD2 (0.61) | DRD2SIGMAR1DRD3HTR6NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2018-11-20 | — | — | US | claimed |
| US-9139525-B2 | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-09-22 | — | — | US | claimed |
| EP-2146961-B1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | IVAX INT GMBH (CH) | 2014-01-29 | — | — | EP | claimed |
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2024-07-16 | — | — | US | disclosed |
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2024-07-16 | — | — | US | disclosed |
| US-20230355595-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | US | disclosed |
| US-20230330073-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| US-20230190724-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| US-20230181548-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-15 | — | — | US | disclosed |
| US-20230165849-A2 | USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-06-01 | — | — | US | disclosed |
| EP-4049998-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd. (IL) | 2022-08-31 | — | — | EP | disclosed |
| US-20150209344-A1 | HYDROBROMIDE SALT OF PRIDOPIDINE | IVAX International GmbH (CH) | 2015-07-30 | — | — | US | disclosed |
| US-9012476-B2 | Hydrobromide salt of pridopidine | IVAX International GmbH (CH) | 2015-04-21 | — | — | US | disclosed |
| EP-2787997-A1 | THE HYDROBROMIDE SALT OF PRIDOPIDINE | IVAX International GmbH (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2146961-B1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | IVAX INT GMBH (CH) | 2014-01-29 | — | — | EP | disclosed |
| WO-2013086425-A1 | THE HYDROBROMIDE SALT OF PRIDOPIDINE | IVAX International GmbH (CH) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150406-A1 | HYDROBROMIDE SALT OF PRIDOPIDINE | IVAX International GmbH (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| EP-2146961-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | CHRM4, GPR4, HTR4 | DRD2 66/4885SIGMAR1 27/4885DRD3 37/4885 |
| US-20230355595-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | HTT, PARK7, DRD1 | DRD2 4/4885SIGMAR1 377/4885DRD3 25/4885 |
| US-20130150406-A1 | HYDROBROMIDE SALT OF PRIDOPIDINE | HTT, HYPK, SLC6A3 | DRD2 5/4885SIGMAR1 372/4885DRD3 33/4885 |
| US-20230181548-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PDE12, PDE3A, PDE3B | DRD2 16/4885SIGMAR1 341/4885DRD3 44/4885 |
| US-20230190724-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE | SMN1; SMN2, LPXN, SNCA | DRD2 49/4885SIGMAR1 817/4885DRD3 209/4885 |
| US-12036213-B2 | Pridopidine for treating drug induced dyskinesias | SLC6A3, QDPR, PARK7 | DRD2 5/4885SIGMAR1 1492/4885DRD3 29/4885 |
| US-20230165849-A2 | USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME | QDPR, PRPH, PDE6A | DRD2 13/4885SIGMAR1 3240/4885DRD3 41/4885 |
| US-20150209344-A1 | HYDROBROMIDE SALT OF PRIDOPIDINE | HTT, HYPK, SLC6A3 | DRD2 5/4885SIGMAR1 372/4885DRD3 33/4885 |
| US-20230330073-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | HTT, HYPK, PARK7 | DRD2 4/4885SIGMAR1 268/4885DRD3 33/4885 |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.